Term ends Jun 12, 2033 · High confidence
20-year base term ends Jun 12, 2033
Held by Quiapeg Pharmaceuticals AB
Filed Sep 18, 2020 as application 17/025,233 · Granted Nov 29, 2022
Base term, 20 years from filing
Today
2013
2033
Clock starts
Jun 12, 2013
Jun 12, 2013
Term ends
Jun 12, 2033
Jun 12, 2033
Granted
Nov 29, 2022
Nov 29, 2022
base term
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,220,789, US 9,849,187, to Jun 12, 2033. The term already ends on or before that date, so the cap shortened nothing.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 12, 2013, when application PCT/IB2013/001885, the earliest non-provisional in its chain, was filed (this one was filed Sep 18, 2020) | Jun 12, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,220,789, US 9,849,187) | resolves to Jun 12, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 12, 2033 | High confidence |
This family
| US 10,010,621 | Lapsed on the fee record Jul 2026 | Jul 2026 |
| US 10,383,946 | In force Jun 2033 | Jun 2033 |
| US 10,806,796 | Lapsed on the fee record Oct 2024 | Oct 2024 |
| US 11,510,989 | this patent Jun 2033 | Jun 2033 |
| Application 17/974,258 | Abandoned not computed | not computed |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 29, 2020 Reel 53921, frame 489 | Kwiatkowski, Marek | Quiapeg Pharmaceuticals AB | Assignment of Assignor's Interest |
| Sep 29, 2020 Reel 53921, frame 520 | Kwiatkowski, Marek | Quiapeg AB | Assignment of Assignor's Interest |
| Sep 29, 2020 Reel 54232, frame 766 | Quiapeg AB | Quiapeg Pharmaceuticals AB | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2033
Term ends Jun 12, 2033.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,220,789, US 9,849,187, ends no earlier than this term, so it caps nothing.
Citations
2
later US patents cite this one
That is above the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.